Structural Differences in Meibum From Donors After Hematopoietic Stem Cell Transplantations.
Structural Differences in Meibum From Donors After Hematopoietic Stem Cell Transplantations.
复制标题
造血干细胞移植后供体睑脂的结构差异。
DOI:
10.1097/ico.0000000000001935
复制
发表时间:
2019
期刊:
影响因子:
2.8
通讯作者:
Borchman,Douglas
中科院分区:
文献类型:
--
作者:
Ramasubramanian,Aparna;Blackburn,Ryan;Yeo,Heegook;Sledge,SamiyyahM;Gully,ZaharaN;Singh,Sharika;Mehta,Sanya;Mehta,Aakash;Yappert,MartaC;Borchman,Douglas
Purpose:Meibum is considered to be a key component of tears that serve to protect the eye, and conformational changes in meibum have not been studied extensively within the population of patients who had hematopoietic stem cell transplantation (HSCT). The aim of this study was to determine possible lipid conformational changes in the meibum of patients who had HSCT.Methods:Participants who had HSCT were randomly sampled for this prospective comparative study. Control participants did not have dry eye or had not undergone allogeneic or autologous stem cell transplantation. Fourier-transform infrared spectroscopy was used to measure meibum phase transition.Results:Meibum was collected from both eyes of 36 donors without dry eye (M c) and from 22 patients who had undergone HSCT (M HSCT). There were no significant differences between the phase transition parameters based on gender or race. The following were the significant differences (P< 0.0001) between the parameters for M c compared with M HSCT: lipid order (% trans) at 33.4 C increased from 40 (1) to 54 (2), cooperativity decreased from 7.9 (0.4) to 5.4 (0.3), the phase transition temperature (o C) increased from 30.3 (0.4) to 34.2 (0.9), and the magnitude of the phase transition (cm− 1) increased from 4.0 (0.1) to 4.7 (0.5)(standard error of the mean).Conclusions:Conformational and thermodynamic differences were observed between M c and M HSCT. The changes observed in the lipid conformation of meibum from patients receiving HSCTs suggest that meibum composition changes after stem cell transplantation, and clinicians should consider treating the meibomian glands to improve the ocular surface.